Search results for "Urticària -- Tractament"

showing 2 items of 2 documents

The global burden of chronic urticaria for the patient and society*

2020

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this …

Pediatricsmedicine.medical_specialtyUrticariaOmalizumabDermatologyOmalizumabDisease030207 dermatology & venereal diseases03 medical and health sciencesIndirect costs0302 clinical medicineQuality of lifemedicineHumansChronic UrticariaDepression (differential diagnoses)business.industryUrticària -- TractamentDermatology Life Quality IndexMiddle AgedSalut públicaEuropeSexual dysfunctionQualitat de vidaChronic DiseasePresenteeismQuality of LifeIndicadors econòmicsFemalemedicine.symptombusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab

2018

Urticariabusiness.industryImmunologyUrticària -- TractamentTotal igeOmalizumabOmalizumabImmunoglobulin E030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineText mining030228 respiratory systemAnti-Allergic AgentsChronic DiseaseImmunologyHumansImmunology and AllergyMedicineDrug Monitoringbusinessmedicine.drug
researchProduct